Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)

Objective: ST-segment Elevation Myocardial Infarction (STEMI) occurs as a result of acute occlusion of the coronary artery. Despite successful reperfusion using percutaneous coronary intervention (PCI), a large percentage of myocardial cells die after reperfusion which is recognized as ischemia/repe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zahra Solati, Arun Surendran, Andrea Edel, Marynia Roznik, David Allen, Amir Ravandi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	reperfusion lipidomics oxidized lipid acute myocardial infarction percutaneous coronary intervention Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/54639b5e430b4714ad53db78409f8d65
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54639b5e430b4714ad53db78409f8d65
record_format	dspace
spelling	oai:doaj.org-article:54639b5e430b4714ad53db78409f8d652021-12-01T22:40:30ZIncrease in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)2296-858X10.3389/fmed.2021.716944https://doaj.org/article/54639b5e430b4714ad53db78409f8d652021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.716944/fullhttps://doaj.org/toc/2296-858XObjective: ST-segment Elevation Myocardial Infarction (STEMI) occurs as a result of acute occlusion of the coronary artery. Despite successful reperfusion using percutaneous coronary intervention (PCI), a large percentage of myocardial cells die after reperfusion which is recognized as ischemia/reperfusion injury (I/R). Oxidized phosphatidylcholines (OxPCs) are a group of oxidized lipids generated through non-enzymatic oxidation and have pro-inflammatory properties. This study aimed to examine the roles of OxPCs in a clinical setting of myocardial I/R.Methods: Blood samples were collected from STEMI patients at presentation prior to primary PCI (PPCI) (Isch) and at 4 time-points post-PPCI, including 2 h (R-2 h), 24 h (R-24 h), 48 h (R-48 h), and 30 days (R-30 d) post-PPCI. As controls, blood samples were collected from patients with non-obstructive coronary artery disease after diagnostic coronary angiography. Aspiration thrombectomy was also performed in selected STEMI patients. High-performance lipid chromatography-electrospray mass spectrometry (LC-MS/MS) was used for OxPCs analysis.Results: Twenty-two distinct OxPC species were identified and quantified in plasma samples in patients presenting with STEMI. These compounds were categorized as fragmented and non-fragmented species. Total levels of OxPCs did not significantly differ between Isch and control groups. However, total levels of fragmented OxPCs increased significantly in the ischemic period compared with controls (Isch: 4.79 ± 0.94, Control: 1.69 ± 0.19 ng/μl of plasma, P < 0.05). Concentrations of non-fragmented OxPCs had significant reductions during ischemia compared to the control group (Isch: 4.84 ± 0.30, Control: 6.6 ± 0.51 ng/μl, P < 0.05). Levels of total OxPCs in patients with STEMI were not significantly different during reperfusion periods. However, fragmented OxPCs levels were elevated at 48 h post-reperfusion and decreased at 30 days following MI, when compared to R-2 h and R-24 h time points (Isch: 4.79 ± 0.94, R-2 h: 5.33 ± 1.17, R-24 h: 5.20 ± 1.1, R-48 h: 4.18 ± 1.07, R-30 d: 1.87 ± 0.31 ng/μl, P < 0.05). Plasma levels of two fragmented OxPCs, namely, POVPC and PONPC were significantly correlated with peak creatine kinase (CK) levels (P < 0.05). As with plasma levels, the dominant OxPC species in coronary aspirated thrombus were fragmented OxPCs, which constituted 77% of total OxPC concentrations.Conclusion: Biologically active fragmented OxPC were elevated in patients presenting with STEMI when compared to controls. PONPC concentrations were subsequently increased after PPCI resulting in reperfusion. Moreover, levels of POVPC and PONPC were also associated with peak CK levels. Since these molecules are potent stimulators for cardiomyocyte cell death, therapeutics attenuating their activities can result in a novel therapeutic pathway for myocardial salvage for patients undergoing reperfusion therapy.Zahra SolatiZahra SolatiArun SurendranArun SurendranAndrea EdelAndrea EdelMarynia RoznikDavid AllenAmir RavandiAmir RavandiAmir RavandiAmir RavandiFrontiers Media S.A.articlereperfusionlipidomicsoxidized lipidacute myocardial infarctionpercutaneous coronary interventionMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	reperfusion lipidomics oxidized lipid acute myocardial infarction percutaneous coronary intervention Medicine (General) R5-920
spellingShingle	reperfusion lipidomics oxidized lipid acute myocardial infarction percutaneous coronary intervention Medicine (General) R5-920 Zahra Solati Zahra Solati Arun Surendran Arun Surendran Andrea Edel Andrea Edel Marynia Roznik David Allen Amir Ravandi Amir Ravandi Amir Ravandi Amir Ravandi Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)
description	Objective: ST-segment Elevation Myocardial Infarction (STEMI) occurs as a result of acute occlusion of the coronary artery. Despite successful reperfusion using percutaneous coronary intervention (PCI), a large percentage of myocardial cells die after reperfusion which is recognized as ischemia/reperfusion injury (I/R). Oxidized phosphatidylcholines (OxPCs) are a group of oxidized lipids generated through non-enzymatic oxidation and have pro-inflammatory properties. This study aimed to examine the roles of OxPCs in a clinical setting of myocardial I/R.Methods: Blood samples were collected from STEMI patients at presentation prior to primary PCI (PPCI) (Isch) and at 4 time-points post-PPCI, including 2 h (R-2 h), 24 h (R-24 h), 48 h (R-48 h), and 30 days (R-30 d) post-PPCI. As controls, blood samples were collected from patients with non-obstructive coronary artery disease after diagnostic coronary angiography. Aspiration thrombectomy was also performed in selected STEMI patients. High-performance lipid chromatography-electrospray mass spectrometry (LC-MS/MS) was used for OxPCs analysis.Results: Twenty-two distinct OxPC species were identified and quantified in plasma samples in patients presenting with STEMI. These compounds were categorized as fragmented and non-fragmented species. Total levels of OxPCs did not significantly differ between Isch and control groups. However, total levels of fragmented OxPCs increased significantly in the ischemic period compared with controls (Isch: 4.79 ± 0.94, Control: 1.69 ± 0.19 ng/μl of plasma, P < 0.05). Concentrations of non-fragmented OxPCs had significant reductions during ischemia compared to the control group (Isch: 4.84 ± 0.30, Control: 6.6 ± 0.51 ng/μl, P < 0.05). Levels of total OxPCs in patients with STEMI were not significantly different during reperfusion periods. However, fragmented OxPCs levels were elevated at 48 h post-reperfusion and decreased at 30 days following MI, when compared to R-2 h and R-24 h time points (Isch: 4.79 ± 0.94, R-2 h: 5.33 ± 1.17, R-24 h: 5.20 ± 1.1, R-48 h: 4.18 ± 1.07, R-30 d: 1.87 ± 0.31 ng/μl, P < 0.05). Plasma levels of two fragmented OxPCs, namely, POVPC and PONPC were significantly correlated with peak creatine kinase (CK) levels (P < 0.05). As with plasma levels, the dominant OxPC species in coronary aspirated thrombus were fragmented OxPCs, which constituted 77% of total OxPC concentrations.Conclusion: Biologically active fragmented OxPC were elevated in patients presenting with STEMI when compared to controls. PONPC concentrations were subsequently increased after PPCI resulting in reperfusion. Moreover, levels of POVPC and PONPC were also associated with peak CK levels. Since these molecules are potent stimulators for cardiomyocyte cell death, therapeutics attenuating their activities can result in a novel therapeutic pathway for myocardial salvage for patients undergoing reperfusion therapy.
format	article
author	Zahra Solati Zahra Solati Arun Surendran Arun Surendran Andrea Edel Andrea Edel Marynia Roznik David Allen Amir Ravandi Amir Ravandi Amir Ravandi Amir Ravandi
author_facet	Zahra Solati Zahra Solati Arun Surendran Arun Surendran Andrea Edel Andrea Edel Marynia Roznik David Allen Amir Ravandi Amir Ravandi Amir Ravandi Amir Ravandi
author_sort	Zahra Solati
title	Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)
title_short	Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)
title_full	Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)
title_fullStr	Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)
title_full_unstemmed	Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)
title_sort	increase in plasma oxidized phosphatidylcholines (oxpcs) in patients presenting with st-elevation myocardial infarction (stemi)
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/54639b5e430b4714ad53db78409f8d65
work_keys_str_mv	AT zahrasolati increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT zahrasolati increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT arunsurendran increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT arunsurendran increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT andreaedel increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT andreaedel increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT maryniaroznik increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT davidallen increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT amirravandi increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT amirravandi increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT amirravandi increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi AT amirravandi increaseinplasmaoxidizedphosphatidylcholinesoxpcsinpatientspresentingwithstelevationmyocardialinfarctionstemi
_version_	1718404100793565184

Increase in Plasma Oxidized Phosphatidylcholines (OxPCs) in Patients Presenting With ST-Elevation Myocardial Infarction (STEMI)

Ejemplares similares